Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-α therapy in a case of chronic hepatitis C

Digestive Diseases and Sciences

Volumn 43, Issue 3, 1998, Pages 529-533

  Sheikh, M Yasin ^a   Wright, Richard A ^a   Burruss, Jyoti B ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Hepatitis C; Interferon ; Porphyria cutanea tarda

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; PORPHYRIA CUTANEA TARDA; RNA, VIRAL;

EID: 15444345904     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018854906444     Document Type: Article

References (27)

1. Elder GH: Porphyria cutania tarda: A multifactorial disease. In Recent Advances in Dermatology, Volume 8. RH Campion, RJ Pye (eds). Edinburgh, Churchill-Livingstone, 1990, pp 55-69
2. Fargion S, Piperno A, Capellini MD, Sampiertr M, Fracanzani AL, Romano R, Caldarelli R, Marcelli R, Vecchi L, Fiorclli G: Hepatitis C virus and porphyria cutanea tarda: Evidence of strong association. Hepatology 16:1322-1326, 1992
3. DeCastro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L, Garcia-Monzon C, Sequi J, Moreno-Otero R: Hepatitis C antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 17:551-557, 1993
4. Lacour JP, Bodokh I, Castanet J, Bekri S, Ortonne JP: Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 128:121-123, 1993
5. Herrero C, Vincente A, Bruguera M, Ercilla S, Barrera JM, Vidai J, Teres J, Mascaro JM, Rodes J: Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 341:788-789, 1993
6. Murphy A, Dooley S, Hillary IB, Murphy GM: HCV infection in porphyria cutanea tarda. Lancet 341:1534-1535, 1993
7. Davis GL, Balart LA, Schiff ER, Linsday K, Bodenheimer H, Perillo R, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
8. Shindo M, Di Bisceglie A, Cheung L, Wai-Kuo Shih J, Cristiano K, Feinstone S, Hoofnagle J: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115:700-704, 1991
9. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Zhi-Bing Y, Weiland O: Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology 21:916-922, 1995
10. Siegel LB, Eber BB: Porphyria cutanea tarda remission. Ann Intern Med 121:304-309, 1994 (letter)
11. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M: Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 22:249-250, 1995
12. Grasset D, Nougue J, Seigneurie C, Landreaud M, Voigt JJ: Porphyria cutanea tarda and chronic hepatitis C. Course after interferon therapy. Gastroenterol Clin Biol 18:1148-1149, 1994 (letter)
13. Okamoto H, Sugiuama Y, Okada SI, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus bt polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992
14. Baravalle E, Prieto J: Serum antibodies against porphyric hepatocytes in patients with porphyria cutanea tarda and liver disease. Gastroenterology 84:1483-1491, 1993
15. Elder GH, Urquhart AJ, De Salamanca RE, Munoz JJ, Bonkovsky HL: Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1:229-232, 1985
16. Bonkovsky HL: Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology 10:354-364, 1989
17. Ponard T, Leroy V, Cohard M, Thevonot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24:778-789, 1996
18. Hoofnagle JH, DiBisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 336:347-356, 1997
19. Saracco G, Rizzetto M: Predictors of response to interferon therapy. Dig Dis Sci 41:115S-120S, 1996
20. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: Genotype analysis of hepatitis C in American patients. Hepatology 20:1405-1411, 1994
21. Bonkovsky HL, Poh-Fitzpatrick M, Tattrie C, DiBiscglie A: Porphyria cutanea tarda and hepatitis C in the USA. Hepatology 24:486A, 1996
22. Adjarove D, Kerimova M: Effective control of patients with porphyria cutanea tarda by measuring plasma uroporphyrin. Clin Exp Dermatol 16:254-257, 1991
23. Lundvall O: Phlebotomy treatment of porphyria cutanea tarda. Acta Derm Venereol Suppl (Stockh) 100:107-118, 1982
24. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon alfa therapy is influenced by the iron content of liver. J Hepatol 20:410-415, 1994
25. Braun W, Levy HB: Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med 141:769-773, 1972
26. Johnson HM: Interferon-mediated modulation of immune system. In Mechanisms of Interferon Actions, Volume 2. LM Pfeffer (ed). Boca Raton, Florida, CRC Press, 1987, pp 59-77
27. Ohkawa ZY, Takahashi H, Aizawa Y, Watanabe F, Toda G: Increased serum level of interleukin-1 receptor antagonist correlates with efficacy of interferon therapy and HCV-RNA level in chronic hepatitis C. Hepatology 24:155A, 1996